key: cord-1031963-rsgdaogj authors: Beesley, Richard P; Costello, Wendy; Angevare, Saskya P; Wouters, Carine; Wulffraat, Nico; Uzie, Yosef title: Survey of adult and paediatric rheumatology patients suggests information about COVID-19 vaccination will aid uptake date: 2021-02-16 journal: Rheumatology (Oxford) DOI: 10.1093/rheumatology/keab169 sha: aceecc4e5022b01d2fcd8ac7a3ff4ddc4c66206b doc_id: 1031963 cord_uid: rsgdaogj nan Dear Editor, Survey of adult and paediatric rheumatology patients suggests information about COVID-19 vaccination will aid uptake. The COVID-19 European Patient Registry (EPR) is a longitudinal study (1) developed by parents of children and young people representing the European Network for Childhood Arthritis (ENCA), with support and involvement from individuals and organisations across Europe, including adult patients and the Paediatric Rheumatology European Society (PReS); a copy of the survey is provided in the supplementary document. Adult patients with rheumatic, autoimmune and autoinflammatory conditions and parents of paediatric patients completed weekly surveys from April to December 2020. A total of 4,336 participants from 58 countries took part in the EPR and 2.9% of each cohort have been diagnosed with COVID-19, with only 10 adults and 1 child admitted to hospital. In December 2020, participants were asked "When a vaccine against COVID-19 is available, will you have the vaccine when you are offered it?" They were also asked if they have had the seasonal flu vaccine and, in both cases, invited to explain why not, if applicable, through free-text questions. Overall, 1,505 adult and 140 paediatric patients answered these questions. Of them, 87% of adults and 66% of children responded that they would have the COVID-19 vaccine. A further 11% of adults and 31% of children were unsure, leaving just 2% and 3% respectively who do not intend to have the vaccine when it is offered. An analysis of reasons for not having the COVID-19 vaccine offers some insight into patient motivations. Whilst some presented clear medical reasons for not having the vaccine (28% of adult and 28% of paediatric respondents answering this question), such as prior anaphylaxis, currently breastfeeding, or direct clinical advice, others indicated a lack of information was preventing them from currently accepting the vaccine (51% adults, 22% paediatric). This lack of information included concerns about possible medication contraindications, safety and efficacy for patients with autoimmune conditions, and side-effects. Others misunderstood the development protocol for the vaccine or its purpose, leading to lack of trust (18% adults, 22% paediatric). Parents of children within the EPR also expressed concerns about suitability of the vaccine for under-16-year-olds (28% of parents responding to this question), but were broadly supportive of having a vaccine once approved for their use. We recognise that some patients have decided against having the vaccine for ethical reasons, and a very small number due to conspiracy theories or misrepresentation of the dangers of COVID-19 infection. However, these represent a very small minority of patients within our cohort. Table 1 shows the broad themes and specific concerns reported by participants, along with an estimation of the benefit of directed guidance for these patient groups. It is important that clear information is prepared, agreed and shared promptly through national and international professional bodies, and through clinical teams. Unlike current generic advice, this should address the specific concerns raised by rheumatology patients through the EPR. It is our opinion that clear, concise and accessible information from a trusted source will support and encourage many of these patients to make an informed choice about COVID-19 vaccination, leading to an increase in the uptake of the vaccine amongst these at-risk patients. The PRES website has guidelines for clinicians (2) . Ultimately, it will also reduce the burden on individual rheumatology teams, as fewer patients will contact them for vaccine advice. We also urge that the stage 2/3 trials for the COVID-19 vaccines amongst children and young people be accelerated. Questions added after initial launch are indicated in blue italics, bracketed. The COVID-19 (Coronavirus) pandemic has quickly infected hundreds of thousands of people worldwide. While many people with COVID-19 infections have mild or no symptoms, a significant proportion of patients can become quite ill. At this time, little is known about how patients with rheumatic diseases or autoimmune conditions, many of whom use medications and drugs that suppress the immune system, are affected by the virus. You will be able to join the study by completing this initial survey that will ask about your medical history and medications that you take. Then, every week we will ask you to fill in a short survey to note any symptoms that you may have developed and whether you have been diagnosed with COVID-19. If so, we will ask you for more information about how you were treated and how you recovered from the disease. We need to collect your email address so that we can send you the follow-up surveys. However, your email address is removed from the data before it is analysed. We will never share your email address with anyone else. Please do not submit any other personal information (such as your name, address or contact details) with this form. You do not have to complete the form and are free to leave the study at any time. Any treatment or support you are receiving will not be affected if you choose not to take part. Information collected will be analysed anonymously by our research consortium. Your anonymous data, along with that of other participants, will be analyzed together to improve our understanding of how COVID-19 affects patients with rheumatic and autoimmune diseases. Your anonymous data will be shared with researchers to support the analysis of the results. Individual participants will never be identified. We plan to present the results of our study in various medical and scientific conferences, as well as publishing our conclusions in various medical journals. A copy of our privacy notice can be found on our website [link] . In this survey we ask about 'rheumatological conditions'. This also includes autoinflammatory diseases and autoimmune conditions. The information you provide in this survey is not shared with your doctor or healthcare provider. If you are concerned about your symptoms or health, you must seek advice from your doctor. Proceedings of the 26th European Paediatric Rheumatology Congress: part 2. Pediatr Rheumatol Guidelines and Recommendations The authors declare no conflicts of interest.There are no funders to report for this submission Data available with a request.